University of Minnesota. Driven to Discover.
Narrow results
Response to seasonal flu, H7N9, MERS, and other threats could be markedly diminished.
Clinical trials will test a candidate vaccine for H7N9 flu in varying doses, some with immune boosters.
A new molecular strategy could diffuse some of the controversy over lab-modified flu viruses.
Will future research include lab-modified strains that are more transmissible and require tighter safety measures?
Experts say some properties of H7 viruses may lend themselves to human adaptation.
Get news & practices.
Sign up now»
Unrestricted financial support provided by
Become an underwriter»